Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: A double-blind, placebo-controlled trial [1]

Digestive Diseases and Sciences

Volumn 44, Issue 6, 1999, Pages 1220-1221

  Gionchetti, P ^a   Rizzello, F ^a   Ferrieri, A ^a   Venturi, A ^a   Brignola, C ^a   Ferretti, M ^a   Peruzzo, S ^a   Miglioli, M ^a   Campieri, M ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; CORTICOSTEROID; METHYLPREDNISOLONE; RIFAXIMIN; TOBRAMYCIN;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; GASTROINTESTINAL ENDOSCOPY; HUMAN; LETTER; PRIORITY JOURNAL; STEROID THERAPY; ULCERATIVE COLITIS;

COLITIS, ULCERATIVE; DOUBLE-BLIND METHOD; GASTROINTESTINAL AGENTS; HUMANS; PILOT PROJECTS; PLACEBOS; RIFAMYCINS;

EID: 0033059934     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1026648812439     Document Type: Letter

References (5)